Figures & data
Table 1. Characteristics of studies.
Figure 4. Network diagram for the repigmentation rate ≥ 75%. EL: excimer laser; HB: hydrocortisone 17-butyrate cream; MF: mometasone furoate; PRP: platelet-rich plasma.
![Figure 4. Network diagram for the repigmentation rate ≥ 75%. EL: excimer laser; HB: hydrocortisone 17-butyrate cream; MF: mometasone furoate; PRP: platelet-rich plasma.](/cms/asset/c2ac4a0e-befa-471c-bb92-14354165df22/ijdt_a_2302064_f0004_c.jpg)
Figure 5. Network diagram for the repigmentation rate ≤ 25%. EL: excimer laser; MF: mometasone furoate; PRP: platelet-rich plasma.
![Figure 5. Network diagram for the repigmentation rate ≤ 25%. EL: excimer laser; MF: mometasone furoate; PRP: platelet-rich plasma.](/cms/asset/90146b8a-48c9-441f-8c7e-e89fbf311ab5/ijdt_a_2302064_f0005_c.jpg)
Table 2. Network meta-analysis of the repigmentation rate (≥75%).
Figure 6. Surfaces under the cumulative ranking curve (SUCRA) probability line chart for the repigmentation rate ≥ 75%. EL: excimer laser; HB: hydrocortisone 17-butyrate cream; MF: mometasone furoate; PRP: platelet-rich plasma.
![Figure 6. Surfaces under the cumulative ranking curve (SUCRA) probability line chart for the repigmentation rate ≥ 75%. EL: excimer laser; HB: hydrocortisone 17-butyrate cream; MF: mometasone furoate; PRP: platelet-rich plasma.](/cms/asset/271ba232-f790-402c-824c-f8481d61b3af/ijdt_a_2302064_f0006_c.jpg)
Table 3. Surfaces under the cumulative ranking curve ranking for repigmentation rates (≥75% and ≤25%).
Table 4. Network meta-analysis of the repigmentation rate (≤25%).
Figure 7. Surfaces under the cumulative ranking curve (SUCRA) probability line chart for the repigmentation rate ≤ 25%. EL: excimer laser; MF: mometasone furoate; PRP: platelet-rich plasma.
![Figure 7. Surfaces under the cumulative ranking curve (SUCRA) probability line chart for the repigmentation rate ≤ 25%. EL: excimer laser; MF: mometasone furoate; PRP: platelet-rich plasma.](/cms/asset/aeb68e8e-304b-4a6f-b883-718c559985aa/ijdt_a_2302064_f0007_c.jpg)
Table 5. Adverse events reported in included studies.
Figure 8. Funnel plot for the repigmentation rate ≥ 75%. EL: excimer laser; AO: antioxidant; CAL: calcipotriol; CLO: clobetasol; HB: hydrocortisone 17-butyrate cream; MF: mometasone furoate; TAC: tacalcitol; TRL: tacrolimus; PRP: platelet-rich plasma.
![Figure 8. Funnel plot for the repigmentation rate ≥ 75%. EL: excimer laser; AO: antioxidant; CAL: calcipotriol; CLO: clobetasol; HB: hydrocortisone 17-butyrate cream; MF: mometasone furoate; TAC: tacalcitol; TRL: tacrolimus; PRP: platelet-rich plasma.](/cms/asset/53bf4401-c9db-414d-9868-27b8bd947b2d/ijdt_a_2302064_f0008_c.jpg)
Figure 9. Funnel plot for the repigmentation rate ≤ 25%. EL: Excimer laser; AO: antioxidant; CAL: calcipotriol; CLO: clobetasol; MF: mometasone furoate; TAC: tacalcitol; TRL: tacrolimus; PRP: platelet-rich plasma.
![Figure 9. Funnel plot for the repigmentation rate ≤ 25%. EL: Excimer laser; AO: antioxidant; CAL: calcipotriol; CLO: clobetasol; MF: mometasone furoate; TAC: tacalcitol; TRL: tacrolimus; PRP: platelet-rich plasma.](/cms/asset/3a1044ae-ab51-4cce-bae3-2cb096868c48/ijdt_a_2302064_f0009_c.jpg)
Supplemental Material
Download PDF (199.8 KB)Data availability statement
The data of this study are available from the corresponding author upon reasonable request.